Codexis PE Ratio 2009-2021 | CDXS

Current and historical p/e ratio for Codexis (CDXS) from 2009 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Codexis PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Codexis PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 29.75 0.00
2021-06-30 22.66 $-0.37 0.00
2021-03-31 22.89 $-0.41 0.00
2020-12-31 21.83 $-0.40 0.00
2020-09-30 11.74 $-0.35 0.00
2020-06-30 11.40 $-0.24 0.00
2020-03-31 11.16 $-0.25 0.00
2019-12-31 15.99 $-0.21 0.00
2019-09-30 13.72 $-0.21 0.00
2019-06-30 18.43 $-0.26 0.00
2019-03-31 20.53 $-0.21 0.00
2018-12-31 16.70 $-0.22 0.00
2018-09-30 17.15 $-0.19 0.00
2018-06-30 14.40 $-0.36 0.00
2018-03-31 11.00 $-0.42 0.00
2017-12-31 8.35 $-0.50 0.00
2017-09-30 6.65 $-0.65 0.00
2017-06-30 5.45 $-0.41 0.00
2017-03-31 4.80 $-0.23 0.00
2016-12-31 4.60 $-0.22 0.00
2016-09-30 4.44 $-0.14 0.00
2016-06-30 4.03 $-0.04 0.00
2016-03-31 3.11 $-0.23 0.00
2015-12-31 4.23 $-0.20 0.00
2015-09-30 3.39 $-0.14 0.00
2015-06-30 3.89 $-0.39 0.00
2015-03-31 4.56 $-0.47 0.00
2014-12-31 2.52 $-0.50 0.00
2014-09-30 2.33 $-0.77 0.00
2014-06-30 1.46 $-0.89 0.00
2014-03-31 2.04 $-1.00 0.00
2013-12-31 1.40 $-1.08 0.00
2013-09-30 1.76 $-1.23 0.00
2013-06-30 2.21 $-1.05 0.00
2013-03-31 2.39 $-0.87 0.00
2012-12-31 2.21 $-0.83 0.00
2012-09-30 3.03 $-0.57 0.00
2012-06-30 3.71 $-0.59 0.00
2012-03-31 3.65 $-0.58 0.00
2011-12-31 5.30 $-0.47 0.00
2011-09-30 4.57 $-0.33 0.00
2011-06-30 9.63 $-0.33 0.00
2011-03-31 11.82 $-0.34 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.923B $0.069B
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis? proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76